Eloxx Pharmaceuticals, INC 8-K filings

Eloxx Pharmaceuticals reported strong Q2 2026 results, highlighted by a $66 million public offering, Nasdaq uplisting, and progress in clinical trials for exaluren in rare kidney diseases.

Eloxx Pharmaceuticals has appointed two new directors and implemented a 1-for-11 reverse stock split, reducing authorized shares.

Eloxx Pharmaceuticals stockholders approved a reverse stock split and an increase in equity incentive plan shares.

Eloxx Pharmaceuticals announces the resignation of director Ms. Lindsay Androski, effective August 6, 2025, citing no disagreements with company operations.

Eloxx Pharmaceuticals' Board of Directors approved a stock option repricing for the CEO, reducing the exercise price to $0.0001 per share and accelerating the vesting of existing options.

Eloxx Pharmaceuticals has amended its loan agreement with Hercules Capital and entered into a royalty agreement with SD MF, securing additional funding and establishing revenue-sharing terms.

Eloxx Pharmaceuticals' Board of Directors approved a stock option repricing for the CEO, reducing the exercise price to $0.90 per share.

Eloxx Pharmaceuticals has granted Almirall exclusive global rights to develop and commercialize its drug candidate ZKN-013, receiving an upfront payment of $3 million and potentially up to $470 million in milestone payments.